Given that Wnt/β-catenin signalling has been shown to be activated in BP-CML [22], we tested whether CK1α or destabilization of β-catenin is required for the anti-CML effects of pyrvinium. This evidence concerns the gene CSNK1A1 and chronic myelogenous leukemia, BCR-ABL1 positive.